IL-33/IL-31 Axis in Osteoporosis

Targeting the IL-12/IL-23 axis

Combination immune checkpoint blockade has demonstrated significant clinical responses in cancers infiltrated by T cells. Many tumors contain high proportions of myeloid cells and these can secrete immunosuppressive cytokines like IL-23. Our data suggest the clinical potential of using anti-CD40 (push) and anti-IL-23 mAbs (pull) to tip the IL-12/23 balance in established tumors and act as an al...

Elevated Responsiveness to IL - 31 Receptor ( IL - 31 RA ) Knockout Mice

The IL-23/IL-17 axis in inflammation.

IL-23 induces the differentiation of naive CD4(+) T cells into highly pathogenic helper T cells (Th17/Th(IL-17)) that produce IL-17, IL-17F, IL-6, and TNF-alpha, but not IFN-gamma and IL-4. Two studies in this issue of the JCI demonstrate that blocking IL-23 or its downstream factors IL-17 and IL-6, but not the IL-12/IFN-gamma pathways, can significantly suppress disease development in animal m...

The Role of IL-23/IL-17 Axis in Lupus

The IL-23/IL-17 axis in psoriatic arthritis.

Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory disease, affecting both the skin and joints. Disease progression is associated with aberrant cytokine expression, and TNF blockade is the most successful therapy to date. However, not all patients are responsive to anti-TNF treatment, highlighting the need to better understand the cellular and molecular mechanisms that govern ...